Strides Pharma Faces Significant Stock Decline Amid Broader Market Weakness

Strides Pharma Science has experienced a notable decline today, with its stock price dropping by 6.37% as of July 31, 2025. This performance marks a significant underperformance compared to the broader sector, lagging by 4.86%. The stock has faced consecutive losses over the past two days, accumulating a total decline of 6.82% during this period.
Opening the day with a gap down of 3.83%, Strides Pharma touched an intraday low of Rs 884.75, reflecting a decrease of 6.61%. Despite this downturn, the stock remains above its 50-day, 100-day, and 200-day moving averages, although it is currently below its 5-day and 20-day moving averages.

In the broader market context, the Sensex opened lower at 80,695.50, down 786.36 points, and is trading at 80,872.14, a decline of 0.75%. The Sensex has been on a downward trend, losing 1.97% over the past three weeks. In terms of longer-term performance, Strides Pharma has shown resilience, with a 73.50% increase over the past year, significantly outperforming the Sensex, which has seen a decline of 1.06% in the same timeframe.